ANG Lifesciences India Reports Mixed Financial Results Amidst Operational Challenges in December 2024

ANG Lifesciences India has recently reported its financial results for the quarter ending December 2024, revealing a complex picture of performance within the pharmaceuticals and drugs industry. The company's net sales for the quarter reached Rs 24.73 crore, reflecting a year-on-year growth of 33.32%, indicating a positive near-term sales trend.
However, several challenges are evident in the financial metrics. The operating profit to interest ratio has reached its lowest point in five quarters at -1.08 times, suggesting difficulties in managing interest payments. Additionally, both the inventory turnover ratio and the debtors turnover ratio have also hit their lowest levels in recent periods, indicating a slowdown in the pace of selling inventory and settling debts, respectively.

Profit after tax (PAT) has shown a decline, with a reported figure of Rs -10.35 crore, marking a year-on-year decrease of 29.79%. Furthermore, cash and cash equivalents have fallen to Rs 3.96 crore, the lowest in the last six half-yearly periods, raising concerns about short-term liquidity. The debt-equity ratio has reached its highest level in five half-yearly periods at 1.20 times, suggesting an increased reliance on borrowing for operational funding.

In light of these developments, ANG Lifesciences has experienced adjustments in its evaluation.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.